Antimicrobial resistance: why it matters and what is being done

What resistance is and how it develops

Antibiotics kill bacteria or stop them growing. But whenever they are used, any bacteria that happen to survive — because of a chance mutation or a resistance gene — go on to multiply, while the susceptible ones die off. Over time, and with repeated exposure, resistant strains come to dominate. This is ordinary evolution under pressure, sped up by every unnecessary or incomplete course of antibiotics. Bacteria can also swap resistance genes between each other, which is why resistance can spread quickly. The same principle applies to antivirals, antifungals and antiparasitics — hence the broader term antimicrobial resistance.

Why it is such a serious threat

Modern medicine quietly depends on effective antibiotics. Hip replacements, chemotherapy, organ transplants, intensive care and caesarean sections all rely on being able to prevent or treat infection. If common bacteria become resistant to most available drugs, routine procedures become far more dangerous and some infections become untreatable. Estimates attribute well over a million deaths a year globally to drug-resistant infections, with the toll projected to rise. It is, in effect, the erosion of a foundation the rest of medicine is built on.

The solutions: using what we have wisely

The first line of defence is antimicrobial stewardship — using antibiotics only when they will help, choosing the right drug, dose and duration, and stopping when appropriate. Much resistance is driven by unnecessary prescribing (for example, antibiotics for viral coughs and colds, which they do not treat) and by use in agriculture. Practical measures include better diagnostics to tell bacterial from viral infection quickly, infection prevention (hand hygiene, vaccination, clean water and sanitation), and public education so people do not expect or demand antibiotics for self-limiting illnesses.

The solutions: new drugs and new incentives

The other front is replenishing the arsenal. Developing new antibiotics is scientifically hard and commercially unattractive — a successful new antibiotic should be used sparingly, which undercuts the usual business model. Novel funding approaches try to fix this, including "subscription" models (such as the one piloted in England) that pay developers for access to a drug rather than by volume sold, deliberately decoupling reward from use. Alongside new antibiotics, researchers are pursuing alternatives such as bacteriophage therapy, vaccines to prevent resistant infections in the first place, and rapid diagnostics. No single measure is enough; slowing AMR needs all of them together.